[Comparative analysis of clinical characteristics and prognosis between bacterial necrotizing pneumonia and Mycoplasma pneumoniae necrotizing pneumonia in children]

Zhonghua Er Ke Za Zhi. 2019 Aug 2;57(8):625-630. doi: 10.3760/cma.j.issn.0578-1310.2019.08.011.
[Article in Chinese]

Abstract

Objective: To compare the characteristics of Mycoplasma pneumoniae necrotizing pneumonia (MPNP) and bacterial necrotizing pneumonia (BNP), and explore the biomarkers for differentiation of MPNP from BNP. Methods: A retrospective, observational study of 52 necrotizing pneumonia (NP) cases who were hospitalized in our hospital from January 2008 to December 2017 was conducted. According to the pathogen causing NP, patients were divided into two groups, BNP and MPNP, and the clinical manifestations, laboratory data, imaging findings, hospital course and prognosis between these groups were analyzed. Results: This study enrolled 19 boys and 33 girls, and the median ages of patients were 4.4 (0.1-13.8) years old. Of the totally of 52 NP patients, 19 were in the BNP group (9 boys and 10 girls), 33 were in the MPNP group (10 boys and 23 girls). The mean age of MPNP patients was much older than that of BNP patients (5.2 (2.3-13.2) years vs. 1.8 (0.1-13.8) years, Z=-0.128, P<0.01). The number of patients with tachypnea and pleural effusion septation were significantly higher in BNP patients than those in MPNP patients (15 cases vs. 4 cases, χ(2)=23.222, P<0.01; 14 cases vs. 1 case, χ(2)=29.326, P<0.01), which more needed to oxygentherapy (18 cases vs. 12 cases, χ(2)=16.833, P<0.01) and undergo chest drainage (9 cases vs. 4 cases, χ(2)=5.829, P=0.022); while the number of patients required bronchoalveolar lavage was higher in MPNP patients than that in BNP patients (5 cases vs. 32 cases, χ(2)=29.326, P<0.01). The values of white blood cell (WBC) (23.2 (5.2-67.1)×10(9)/L vs. 9.7 (6.3-18.7)×10(9)/L, Z=-4.855, P<0.01), procalcitonin (PCT) (3.69 (0.23-90.15) mg/L vs. 0.28 (0.02-1.44) mg/L, Z=-3.207, P=0.001), C reactive protein (CRP) (160 (94-220) mg/L vs. 90 (5-134) mg/L, Z=-4.337, P<0.01), interleukin (IL)-10 (11.7 (4.2-401.5) ng/L vs. 4.8 (2.0-23.4) ng/L, Z=-2.278, P=0.023), pleural fluid cell count (5 200 (120-50 000)×10(6)/L vs. 790 (68-6 920)×10(6)/L, Z=-3.125, P=0.002), pleural fluid lactic dehydrogenase (LDH) (3 990 (589-29 382) U/L vs. 2 211 (673-3 993) U/L, Z=-2.488, P=0.013) in BNP group were significantly higher than those in MPNP group; while the values of pleural fluid glucose(0.43 (0.03-18.00) mmol/L vs. 5.95 (4.27-7.87) mmol/L, Z=-2.795, P=0.005), serum tumor necrosis factor (TNF)-α (2.3 (1.0-2.8) ng/L vs. 2.6 (1.3-109.2) ng/L, Z=-2.113, P=0.035) and interferon (IFN)-γ (4.8 (2.6-7.7) ng/L vs. 11.9 (2.9-154.6) ng/L, Z=-2.455, P=0.014) were lower in BNP group than those in MPNP group. Meanwhile, the mean time from the onset of symptoms to the discovery of necrotic lesions was longer in MPNP group than that in BNP group ((20.6±6.4) days vs. (14.6±6.2) days, t=3.029, P=0.004). After treatments, all patients were discharged without death, WBC and PCT recovered more quickly in MPNP group than those in BNP group (12 (0-24) days vs. 0 (0-23) days, Z=-4.484, P<0.01; 10 (5-15) days vs. 0 (0-23) days, Z=-3.244, P=0.001). As to prognosis, 34 cases were followed up, and the results showed that patients recovered without surgical intervention, and chest lesions were resolved within 3.0 (1.0-8.0) months, and the time to necrosis disappearance was similar in the BNP group and MPNP greup (3.0 (1.0-8.0) months vs. 3.0 (1.0-8.0) months, Z=-0.128, P=0.001). In receiver operator characteristic curve analysis, the cut-off values for the age, WBC, CRP, PCT, pleural fluid cell count and pleural fluid glucose were set at 2.4 years of age, 17.2×10(9)/L, 157 mg/L, 1.505 mg/L, 2 630×10(6)/L and 3.73 mmol/L, respectively. Conclusions: NP is found to be severe and prolonged, yet, reversible through proper therapy, such as rational antibiotics application. The age, WBC, CRP, PCT, pleural fluid cell count and pleural fluid glucose could be used as biomarkers to differentiate MPNP from BNP in children.

目的: 比较分析儿童细菌性坏死性肺炎(BNP)与肺炎支原体坏死性肺炎(MPNP)的临床特征与预后。 方法: 回顾性收集了浙江大学医学院附属儿童医院自2008年1月至2017年12月期间住院的52例NP患儿临床资料,根据病原菌分为BNP和MPNP,分析比较了两组患儿的临床表现、实验室检查结果、影像学特征、诊治过程及转归情况。 结果: 52例NP患儿,男19例、女33例,年龄4.4(0.1~13.8)岁。其中BNP19例,男9例女10例;MPNP33例,男10例、女23例,MPNP患儿年龄明显大于BNP患儿年龄[5.2(2.3~13.2)岁比1.8(0.1~13.8)岁,Z=-0.128,P<0.01]。BNP患儿与MPNP患儿相比气促和胸腔积液分隔[15例比4例,χ(2)=23.222,P<0.01;14例比1例,χ(2)=29.326,P<0.01]、需要吸氧[18例比12例,χ(2)=16.833,P<0.01]和胸腔闭式引流[9例比4例,χ(2)=5.829,P=0.022]的例数明显多,而BNP患儿行支气管肺泡灌洗的例数明显少[5例比32例,χ(2)=29.326,P<0.01]。实验室检查发现,BNP与MPNP患儿相比白细胞计数[23.2(5.2~67.1)×10(9)/L比9.7(6.3~18.7)×10(9)/L,Z=-4.855,P<0.01]、前降钙素(PCT)[3.69(0.23~90.15)mg/L比0.28(0.02~1.44)mg/L,Z=-3.207,P=0.001]、C反应蛋白(CRP)[160(94~220)mg/L比90(5~134)mg/L,Z=-4.337,P<0.01]、白细胞介素10(IL-10)[11.7(4.2~401.5)ng/L比4.8(2.0~23.4)ng/L,Z=-2.278,P=0.023]、胸腔积液细胞计数[5 200(120~50 000)×10(6)/L比790(68~6 920)×10(6)/L,Z=-3.125,P=0.002]和胸腔积液乳酸脱氢酶(LDH)[3 990(589~29 382)U/L比2 211(673~3 993)U/L,Z=-2.488,P=0.013]均高,而胸腔积液中的葡萄糖[0.43(0.03~18.00)mmol/L比5.95(4.27~7.87)mmol/L,Z=-2.795,P=0.005]、血清肿瘤坏死因子α[2.3(1.0~2.8)ng/L比2.6(1.3~109.2)ng/L,Z=-2.113,P=0.035]和γ干扰素[4.8(2.6~7.7)ng/L比11.9(2.9~154.6)ng/L,Z=-2.455,P=0.014]均低。胸部影像学检查发现,MPNP患儿坏死病灶出现明显晚于BNP患儿[病程第(20.6±6.4)d比(14.6±6.2)d,t=3.029,P=0.004]。经治疗所有患儿均好转出院,但MPNP组WBC和PCT恢复正常时间明显短于BNP组[12(0~24)d比0(0~23)d,Z=-4.484,P<0.01;10(5~15)d比0(0~23)d,Z=-3.244,P=0.001]。有34例患儿进行了长期随访,坏死病灶经3.0(1.0~8.0)个月吸收,BNP和MPNP两组患儿坏死病灶吸收时间[3.0(1.0~8.0)个月比3.0(1.0~8.0)个月,Z=-0.128,P=0.001]上差异无统计学意义。经受试者工作特征曲线曲线下面积计算得出年龄、WBC、CRP、PCT、胸腔积液细胞学计数和胸腔积液葡萄糖6个独立相关因素可作为BNP或MPNP的有价值预测指标,界值分别为年龄2.4岁、WBC 17.2×10(9)/L, CRP 157 mg/L, PCT 1.505 mg/L,胸腔积液细胞学计数2 630×10(6)/L和胸腔积液葡萄糖3.73 mmol/L。 结论: NP临床过程严重、漫长,但经合理抗感染及对症支持治疗大多预后良好。当NP患儿年龄≤2.4岁,WBC≥17.2×10(9)/L,CRP≥157 mg/L,PCT≥1.505 mg/L,胸腔积液细胞学计数≥2 630×10(6)/L,胸腔积液葡萄糖≤3.73 mmol/L,考虑可能是BNP可作为区别BNP和MPNP的指标。.

Keywords: Child; Necrotizing pneumonia; Pneumonia, Mycoplasma; Staphylococcus aureus; Streptococcus pneumoniae.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / therapeutic use
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Male
  • Mycoplasma pneumoniae*
  • Necrosis / pathology*
  • Pneumonia, Mycoplasma / diagnosis*
  • Pneumonia, Mycoplasma / microbiology
  • Pneumonia, Necrotizing / diagnosis*
  • Pneumonia, Necrotizing / microbiology
  • Prognosis
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Biomarkers
  • C-Reactive Protein